Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference
Vor Bio (VOR) management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 17, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Bio (VOR) management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 17, 2026.
The session in London, United Kingdom, is scheduled for 10:30–10:55 am GMT. A live webcast will be accessible through ir.vorbio.com, with a replay available for approximately 30 days following the presentation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London, United Kingdom.
Presentation: Tuesday, November 17, 2026 at 10:30am – 10:55 am GMT
A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Vor Bio routinely posts information that may be important to investors in the “Investors” section of its website. The Company encourages investors to consult that section of its website regularly.
Media & Investor Contacts: Carl Mauch cmauch@vorbio.com